Application of hypaconitine and structural analogue thereof as Sirt3 inhibitor and inducing in-vivo and in-vitro oxidative stress

Abstract

The invention belongs to novel application of hypaconitine as a Sirt3 inhibitor, and particularly discloses application of hypaconitine and a structural analogue thereof as the Sirt3 inhibitor and inducing in-vivo and in-vitro oxidative stress, influence of the hypaconitine on cell Sirt3 protein expression, application of the hypaconitine as the Sirt3 inhibitor, application of the structural analogue of the hypaconitine as the Sirt3 inhibitor. application of the hypaconitine in inhibiting Sirt3 to induce in-vivo and in-vitro oxidative stress, and application of the structural analogue of the hypaconitine in inhibiting Sirt3 to induce in-vivo and in-vitro oxidative stress. The hypaconitine has an obvious inhibition effect on the Sirt3, causes increase of the oxidative stress level, and can be used as the Sirt3 inhibitor for scientific research and drug clinic.

Description

technical field [0001] The invention belongs to the new application of hypoaconitine and its analogues, and in particular relates to the application of hypoaconitine and its structural analogues as Sirt3 inhibitors and inducing oxidative stress in vivo and in vitro. Background technique [0002] NAD-dependent deacetylase Sirt3 is mainly located in mitochondria. As a deacetylase, Sirt3 can make a variety of antioxidant enzymes (including manganese superoxide dismutase MnSOD, catalase, oxygen product dismutase SOD2, gluten Glutathione reductase (GSH, etc.) is activated by deacetylation, and then participates in the regulation of oxidative stress and clears the level of reactive oxygen species. [0003] Hypoaconitine diester-type alkaloid exists in the roots of Ranunculaceae Aconitum, Aconitum brachyphyllum, and Aconitum chinensis, also known as hypoaconitine, hepaaconitine, and homoaconitine. It is reported that hypoaconitine can directly inhibit the production of inflammator...

Images